Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC. The company's drug candidates also comprise ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; and ZL-2302 to treat non-small cell lung cancer. Zai Lab Limited was founded in 2013 and is headquartered in Shanghai, the People's Republic of China.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ZLAB
CUSIPN/A
Phone86-21-6163-2588
Debt
Debt-to-Equity RatioN/A
Current Ratio19.12
Quick Ratio19.12
Price-To-Earnings
Trailing P/E Ratio-9.56
Forward P/E Ratio-15.69
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.77 per share
Price / Book4.77
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees52
Outstanding Shares50,560,000
Market Cap$1.11 billion
Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions
What is Zai Lab's stock symbol?
Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."
What price target have analysts set for ZLAB?
3 brokers have issued 12 month price objectives for Zai Lab's shares. Their predictions range from $32.00 to $43.00. On average, they anticipate Zai Lab's share price to reach $37.50 in the next twelve months. This suggests a possible upside of 64.8% from the stock's current price. View Analyst Price Targets for Zai Lab.
What is the consensus analysts' recommendation for Zai Lab?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zai Lab.
Who are some of Zai Lab's key competitors?
Some companies that are related to Zai Lab include Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC- (GWPH), Madrigal Pharmaceuticals (MDGL), Endo International (ENDP), Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Array Biopharma (ARRY), Opko Health (OPK), Blueprint Medicines (BPMC), Heron Therapeutics (HRTX) and Akcea Therapeutics (AKCA).
Who are Zai Lab's key executives?
Zai Lab's management team includes the folowing people:
- Dr. Ying Du, Chairman & CEO (Age 52)
- Mr. Billy Cho, Chief Financial Officer (Age 40)
- Dr. Ning Xu, Exec. VP of Clinical Operations & Regulatory Affairs (Age 53)
- Dr. Qi Liu, Chief Medical Officer of Oncology (Age 53)
- Dr. James Yan, Exec. VP, Head of Early Devel. & Drug Safety (Age 54)
When did Zai Lab IPO?
(ZLAB) raised $100 million in an initial public offering on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO.
Has Zai Lab been receiving favorable news coverage?
News headlines about ZLAB stock have trended somewhat positive on Monday, according to Accern. Accern scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zai Lab earned a coverage optimism score of 0.11 on Accern's scale. They also gave news stories about the company an impact score of 45.59 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Zai Lab.
Who are Zai Lab's major shareholders?
Zai Lab's stock is owned by a variety of of retail and institutional investors. Top institutional investors include DU YING (17.42%), FMR LLC (10.00%), Orbimed Advisors LLC (3.19%), Gilder Gagnon Howe & Co. LLC (1.70%), Segantii Capital Management Ltd (1.06%) and Millennium Management LLC (0.76%).
Which major investors are selling Zai Lab stock?
ZLAB stock was sold by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Gilder Gagnon Howe & Co. LLC, NINE MASTS CAPITAL Ltd and Bank of America Corp DE.
Which major investors are buying Zai Lab stock?
ZLAB stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Millennium Management LLC, FMR LLC, Segantii Capital Management Ltd and BlackRock Inc..
How do I buy shares of Zai Lab?
Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zai Lab's stock price today?
One share of ZLAB stock can currently be purchased for approximately $22.75.
How big of a company is Zai Lab?
Zai Lab has a market capitalization of $1.11 billion. The company earns $-50,380,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis. Zai Lab employs 52 workers across the globe.
How can I contact Zai Lab?
Zai Lab's mailing address is 1043 HALEI ROAD ZHANGJIANG HI-TECH PARK, SHANGHAI F4, 201210. The company can be reached via phone at 86-21-6163-2588 or via email at [email protected]
MarketBeat Community Rating for Zai Lab (NASDAQ ZLAB)
MarketBeat's community ratings are surveys of what our community members think about Zai Lab and other stocks. Vote "Outperform" if you believe ZLAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZLAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
